{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:41Z","timestamp":1793040881428,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["14-50-00069"],"award-info":[{"award-number":["14-50-00069"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.psychres.2017.09.041","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T12:30:50Z","timestamp":1505910650000},"page":"542-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates"],"prefix":"10.1016","volume":"262","author":[{"given":"Mariia","family":"Dorofeikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Neznanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2017.09.041_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/oxfordjournals.schbul.a033363","article-title":"Neurocognitive and social functioning in schizophrenia","volume":"25","author":"Addington","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2017.09.041_bib2","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1073\/pnas.91.15.7041","article-title":"Memory consolidation and the medial temporal lobe: a simple network model","volume":"91","author":"Alvarez","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.psychres.2017.09.041_bib3","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jpsychires.2013.05.032","article-title":"Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia","volume":"47","author":"Asevedo","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2017.09.041_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2016.03.025","article-title":"Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: the OPUS study","volume":"175","author":"Bergh","year":"2016","journal-title":"Schizophr. Res."},{"issue":"1\u20132","key":"10.1016\/j.psychres.2017.09.041_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psychres.2014.02.015","article-title":"Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment","volume":"217","author":"Bosia","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2017.09.041_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.clinpsy.2.022305.095232","article-title":"Endophenotypes in the genetic analyses of mental disorders","volume":"2","author":"Cannon","year":"2006","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.psychres.2017.09.041_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.schres.2015.02.022","article-title":"Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study","volume":"164","author":"Cuesta","year":"2015","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2017.09.041_bib8","first-page":"250","article-title":"Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia: a systematic review","volume":"24","author":"Cui","year":"2012","journal-title":"Shanghai Arch. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.biopsych.2003.12.010","article-title":"General and specific cognitive deficits in schizophrenia","volume":"55","author":"Dickinson","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2007.03.022","article-title":"C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia","volume":"93","author":"Dickerson","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2017.09.041_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-244X-12-64","article-title":"Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence","volume":"12","author":"Fioravanti","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib12","series-title":"Neuropsychopharmacology: The Fifth Generation of Progress","first-page":"657","article-title":"Neurocognitive functioning in patients with schizophrenia","author":"Goldberg","year":"2002"},{"issue":"1","key":"10.1016\/j.psychres.2017.09.041_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scog.2014.02.001","article-title":"Cognition in schizophrenia: past, present, and future","volume":"1","author":"Green","year":"2014","journal-title":"Schizophr. Res. Cogn."},{"key":"10.1016\/j.psychres.2017.09.041_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/schbul\/sbs146","article-title":"Has the generalized deficit become the generalized criticism?","volume":"39","author":"Green","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2017.09.041_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS","volume":"72","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2017.09.041_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/schbul\/sbl055","article-title":"The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes","volume":"33","author":"Gur","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2017.09.041_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","article-title":"Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment","volume":"158","author":"Harvey","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbj011","article-title":"Negative symptoms and cognitive deficits: what is the nature of their relationship?","volume":"32","author":"Harvey","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.psychres.2017.09.041_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.eurpsy.2011.10.003","article-title":"Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial","volume":"28","author":"Johnsen","year":"2013","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/NDT.S61672","article-title":"Towards a framework for treatment effectiveness in schizophrenia","volume":"10","author":"Juckel","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.psychres.2017.09.041_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2017.09.041_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The brief assessment of cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2017.09.041_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","article-title":"Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol","volume":"161","author":"Keefe","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-642-25758-2_2","article-title":"Cognitive impairment in schizophrenia","volume":"213","author":"Keefe","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.psychres.2017.09.041_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(05)80081-9","article-title":"Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study","volume":"342","author":"Koster","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2017.09.041_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbi004","article-title":"Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study","volume":"31","author":"Kurtz","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2017.09.041_bib27","first-page":"1","article-title":"Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis","volume":"11","author":"Leeson","year":"2009","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.psychres.2017.09.041_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/npp.2010.156","article-title":"Cognitive control deficits in schizophrenia: mechanisms and meaning","volume":"36","author":"Lesh","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2017.09.041_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2017.09.041_bib30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/NDT.S46799","article-title":"Design and validation of standardized clinical and functional remission criteria in schizophrenia","volume":"10","author":"Mosolov","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2017.09.041_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2017.09.041_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fpsyt.2013.00035","article-title":"Executive functioning in schizophrenia","volume":"4","author":"Orellana","year":"2013","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2017.09.041_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/schbul\/sbn044","article-title":"Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders","volume":"35","author":"Reichenberg","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2017.09.041_bib35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.mp.4001548","article-title":"Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF","volume":"9","author":"Rothermundt","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.mp.4000889","article-title":"Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology","volume":"6","author":"Rothermundt","year":"2001","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2017.09.041_bib37","first-page":"19","article-title":"Age differences of neurocognitive deficit in patients with schizophrenia and schizophrenia spectrum disorders on the first stages of illness","volume":"23","author":"Shmukler","year":"2013","journal-title":"Soc. Im. Klin. Psikhiatr."},{"issue":"7","key":"10.1016\/j.psychres.2017.09.041_bib38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/(SICI)1097-4679(199811)54:7<985::AID-JCLP12>3.0.CO;2-G","article-title":"Rey-Osterrieth Complex Figure Test performance in acute, chronic, and remitted schizophrenia patients","volume":"54","author":"Silverstein","year":"1998","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.psychres.2017.09.041_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2008.05.027","article-title":"Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia","volume":"105","author":"Skelley","year":"2008","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.psychres.2017.09.041_bib40","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/jnnp.2006.093427","article-title":"Increased cerebrospinal fluid and serum levels of S100B in first onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone specific enolase from glia or neurons","volume":"77","author":"Steiner","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2017.09.041_bib41","doi-asserted-by":"crossref","first-page":"e43284","DOI":"10.1371\/journal.pone.0043284","article-title":"Validating serum S100B and neuron-specific enolase as biomarkers for the human brain \u2013 a combined serum, gene expression and MRI study","volume":"7","author":"Streitb\u00fcrger","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.psychres.2017.09.041_bib42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1600-0447.2010.01552.x","article-title":"Is late-onset schizophrenia a subtype of schizophrenia?","volume":"122","author":"Vahia","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2017.09.041_bib43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/archpsyc.61.4.346","article-title":"Hippocampal volumes in schizophrenic twins","volume":"61","author":"van Erp","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2017.09.041_bib44","unstructured":"Vasserman, L.I., Cherednikova, T.V., 2011. Psychological assessment of neurocognitive deficit: restandartization and approbation of\u00a0Rey-Osterreith Complex\u00a0figure: methodological recommendations. [In Russian] Saint-Petersburg."},{"issue":"13","key":"10.1016\/j.psychres.2017.09.041_bib45","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0b013e3181d7b45b","article-title":"Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function","volume":"74","author":"Wersching","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.psychres.2017.09.041_bib46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2017.09.041_bib47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/schbul\/sbr064","article-title":"Thinking about the future cognitive remediation therapy \u2014 what works and could we do better?","volume":"37","author":"Wykes","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2017.09.041_bib48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117314592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117314592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T14:57:55Z","timestamp":1551797875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178117314592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":48,"alternative-id":["S0165178117314592"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2017.09.041","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2017.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}